Should microbiological samples be taken routinely when performing revision surgery for post-surgical hematoma after hip or knee replacement? Retrospective study of 78 cases of surgically drained hematoma with a minimum follow-up of 2 years.


Journal

Orthopaedics & traumatology, surgery & research : OTSR
ISSN: 1877-0568
Titre abrégé: Orthop Traumatol Surg Res
Pays: France
ID NLM: 101494830

Informations de publication

Date de publication:
06 2023
Historique:
received: 22 05 2022
revised: 20 09 2022
accepted: 26 09 2022
medline: 23 5 2023
pubmed: 9 3 2023
entrez: 8 3 2023
Statut: ppublish

Résumé

The relationship between the occurrence of a periprosthetic hip or knee joint infection, a post-surgical hematoma and the time to surgical revision, along with the need to take samples for microbiology analysis has not been clearly defined. This led us to perform a retrospective study to: 1) define the rate of infected hematoma and subsequent infection after surgical revision for hematoma and 2) analyze in which time frame the hematoma was likely to be infected. The more time elapsed before the postoperative hematoma is drained surgically after hip or knee replacement, the higher the hematoma infection rate and the late infection rate. Between 2013 and 2021, 78 patients (48 hip and 30 knee replacements) who had a postoperative hematoma without signs of infection upon draining were included in the study. Surgeons decided whether samples for microbiology were collected (33/78 patients (42%)). The data compiled consisted of the patient's demographics, the risk factors for infection, number of infected hematomas, number of subsequent infections at a minimum follow-up of 2 years, and the time to revision surgery (lavage). Of the 27 samples collected from the hematoma during the first lavage, 12/27 (44%) were infected. Of the 51 that did not have samples collected initially, 6/51 (12%) had them collected during the second lavage; 5 were infected and 1 was sterile. Overall, 17/78 (22%) of the hematomas were infected. Conversely, there were no late infections at a mean follow-up of 3.8 years (min 2, max 8) after the hematoma was drained in any of the 78 patients. The median time to revision was 4 days (Q1=2, Q3=14) for non-infected hematomas that were drained surgically versus 15 days (Q1=9, Q3=20) for hematomas that were found to be infected (p=0.005). No hematoma was infected when it was drained surgically within 72hours post-arthroplasty (0/19 (0%)). The infection rate went up to 2/16 (12.5%) when it was drained 3 to 5 days later and 15/43 (35%) when it was drained after more than 5 days (p=0.005). We believe this justifies collecting microbiology samples immediately when the hematoma is drained more than 72hours after the joint replacement procedure. Diabetes was more prevalent in patients who had an infected hematoma (8/17 [47%] versus 7/61 [11.5%], p=0.005). The infection was due to a single bacterium in 65% of cases (11/17); S. epidermidis was found in 59% (10/17) of infections. The occurrence of a hematoma after hip or knee replacement that requires surgical revision is associated with increased risk of infection, since the hematoma infection rate was 22%. Since hematomas drained within 72hours are less likely to be infected, samples do not need to be collected for microbiology at that time. Conversely, any hematomas being drained surgically beyond this time point should be considered as infected, thus microbiology samples should be collected, and empirical postoperative antibiotic therapy initiated. Early revision may prevent the occurrence of late infections. The standard treatment of infected hematomas appears to resolve the infection at a minimum follow-up of 2 years. Level IV Retrospective study.

Identifiants

pubmed: 36889580
pii: S1877-0568(23)00049-X
doi: 10.1016/j.otsr.2023.103585
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103585

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

Lucie Charles (L)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France. Electronic address: lucie.charles3@gmail.com.

Pierre Martinot (P)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France.

Julien Dartus (J)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France.

Eric Senneville (E)

University of Lille, Hauts de France, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France; Service des Maladies Infectieuses et du Voyageur, CH Dron, rue du Président Coty, 59208 Tourcoing, France.

Gilles Pasquier (G)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France.

Sophie Putman (S)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France.

Julien Girard (J)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France; University of Lille, University of Artois, University Littoral Côte d'Opale, EA 7369-URePSS-Unité de Recherche Pluridisciplinaire Sport Santé Société, 59000 Lille, France.

Marie Titecat (M)

University of Lille, Hauts de France, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France; Institute of Microbiology, Lille University Hospital, Centre de Biologie-Pathologie, Rue du Pr. Jules Leclercq, 59037 Lille, France.

Henri Migaud (H)

University of Lille, Hauts de France, 59000 Lille, France; Service d'Orthopédie, Hôpital Salengro, Place de Verdun, CHU Lille, 59000 Lille, France; Northwest Reference Center for Complex Bone and Joint Infections (CRIOAC-G4 Lille-Tourcoing), Centre de Référence pour le traitement des Infections Ostéo-Articulaires Complexes Lille-Tourcoing, rue Emile Laine, 59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH